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The renalase pathway is a previously unrecognized
mechanism for regulating cardiac function and blood
pressure. In this pathway, renalase, a novel secreted amine
oxidase that is inactive at baseline, is rapidly turned on
(B10 fold increase) by either a modest increase in blood
pressure or by brief surges in plasma catecholamines. The
active enzyme degrades circulating catecholamines, causing
a significant fall in blood pressure. Plasma catecholamines
not only activate renalase enzymatic activity but also lead
to a 3–4 fold stimulation of renalase secretion. The renalase
knockout mouse (KO) is hypertensive and exquisitely
sensitive to cardiac ischemia. Abnormalities in the renalase
pathway are present in animal models of chronic kidney
disease (CKD) and hypertension. Two single-nucleotide
polymorphisms (SNPs) in the renalase gene were found to be
associated with essential hypertension in man. Blood
renalase levels are inversely correlated with glomerular
filtration rate (GFR) and are markedly reduced in patients
with end-stage kidney disease (ESRD). We hypothesize that
renalase is secreted into blood by the kidney (although also
expressed in heart, skeletal muscle, and small intestine) and
plays a key role in regulating blood pressure and
cardiovascular function, and that abnormalities in the
renalase pathway contribute to the heightened
cardiovascular risks observed in patients with CKD.
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CARDIOVASCULAR COMPLICATIONS IN CHRONIC KIDNEY
DISEASE
Although it is clear that renal replacement therapy, along
with an aggressive management of infection, hypertension,
hyperlipidemia, and secondary hyperparathyroidism, pro-
longs the life of those with end-stage kidney disease (ESRD),
cardiovascular complications and overall mortality remains
high. Data obtained from dialysis registries indicate a 6- to
10-fold increase in cardiovascular events compared with that
in the non-dialysis population.1 This increased propensity for
cardiovascular disease seems to correlate with extensive
arterial calcification, increased oxidative stress,2 and a
heightened sympathetic tone.3,4 Furthermore, it was not well
recognized, until recently, that cardiovascular disease is also
prevalent and aggressive in patients with moderate reduction
in renal function, such as those with chronic kidney disease
(CKD) stage 3–5, who had not reached end stage and who
were not receiving dialysis treatment. Compared with healthy
controls, patients with CKD are far more likely to develop
cardiovascular disease, and this propensity is not fully
explained by the presence of traditional risk factors such as
hyperlipidemia and hypertension.
Two large recent studies stand out, for they confirm earlier
studies showing excess cardiovascular disease in CKD, and
dramatically highlight the extent of the problem. A secondary
analysis of the VALIANT study indicates that in patients with
preexisting cardiac disease, the estimated risk of death from
any cause over a 2-year period increased as glomerular
filtration rate (GFR) declined, and patients with GFRs of less
than 20ml/min were six times more likely to die than were
those with GFRs above 60ml/min.5 In another study that
examined over 1.1 million enrollees from a single Health
Maintenance Organization in northern California over a
2-year period, it was noted that renal function was an
independent predictor of subsequent cardiac events, hospi-
talization, and overall mortality.6 These findings not only
confirm earlier studies but also bring to light the clinical and
public health importance of CKD.
As approximately 26 million persons suffer from CKD in
the United States alone, it is of utmost importance to gain a
more detailed mechanistic understanding of the link between
kidney and heart disease. Epidemiological data strongly
suggest that although traditional risk factors for cardiac
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disease are prevalent in the CKD population, they do not
seem to fully account for the observed disease burden.
Additional conditions, such as sympathetic activation,
inflammation, and disordered calcium and phosphate
metabolism, are prevalent in CKD and are believed to
increase cardiovascular risk. The development of optimal
management protocols ultimately depends on a deeper
knowledge of the key functions of the kidney, and on the
development of therapeutic tools that can replicate
the kidney’s critical functions and that are applicable to the
management of these non-traditional risk factors.
In the healthy host, extensive cross-talk takes place
between the kidney and the sympathetic nervous system to
regulate important physiological processes. For instance,
renal hemodynamics is regulated by an a1-adrenergic
receptor-mediated pathway, and stimulation of both a1 and
a2 receptors can increase sodium reabsorption.7,8 The
activation of b1 receptors can stimulate renin release from
juxtaglomerular cells. Sympathetic overactivity is prevalent in
patients with renal disease, and has been documented by
microneurography in those with CKD stage 3 and above.9–11
The diseased kidney generates activating afferent signals
through the stimulation of baro- and chemoreceptors. It is
noteworthy that mild parenchymal injury, as can be achieved
by injection of phenol into one pole of the kidney, with no
measurable reduction in GFR, is associated with increased
renal sympathetic outflow. Plasma norepinephrine (NE) is a
valuable, though not perfect, proxy for the activity level of
the sympathetic nervous system. NE levels are determined by
the degree of sympathetic nerve activity, with a greater
overspill of NE into the circulation as nerve activity increases,
and by the capacity of peripheral tissues, such as the kidney,
to metabolize NE. In the physiological state, the kidney takes
up NE and metabolizes it using monoamine oxidase B and
catechol-o-methyl transferase, and as will be described below,
by renalase, a secreted amine oxidase recently discovered in
our laboratory. In patients with ESRD, a significant increase
in plasma NE is associated with a worse prognosis.4,12,13
DISCOVERY OF RENALASE
The kidney plays a key role in fluid and electrolyte balance,
and also serves as an endocrine organ. Indeed, it is the major
site for rennin secretion, and an important source of vitamin
D and erythropoietin. Renalase was identified in the course of
testing the hypothesis that the kidney secretes proteins that
impact cardiovascular health, but are yet to be characterized,
and could represent novel therapeutic targets.14 The Mam-
malian Gene Collection (MGC) database, which at the time
contained over 13,000 entries, was screened using an
algorithm designed to identify putative secreted proteins of
unknown function. The search yielded 114 genes encoding
previously uncharacterized proteins, bearing secretory signal
peptides. Tissue expression was assessed by northern blot and
genes preferentially expressed in the kidney were selected for
further study. Protein secretion was tested in cultured cells
and putative functional domains were identified by computer
analysis. Clone 9, which encodes a protein subsequently
named renalase, was chosen for a more detailed analysis
because renalase is secreted in human plasma and renalase
levels are markedly reduced in patients with ESRD.
The human renalase gene resides on chromosome 10 at
q23.33, encompasses 309,469 base pairs (bp), and has 10
exons. There is evidence for the existence of at least four
alternatively spliced isoforms (Figure 1). The most highly
expressed isoform (renalase1) is 342 aa long, and encoded by
exons 1–4, 6–7, and 9. It is the predominant human renalase
protein (hRenalase) detected in plasma, kidney, heart, skeletal
muscle, and liver. It contains a signal peptide, a flavin
adenine dinucleotide (FAD)-binding region, and an amine
oxidase domain (Figure 2). hRenalase2 is 315 aa long,
encoded by exons, 1–4, 6–7, and 10, and differs from
hRenalase1 at the extreme carboxy terminus. hRenalase3
(exons 1, 4, 6–7, 10) and hRenalase4 (exons 5–9) are
significantly shorter, with 232 and 138 aa, respectively, and
unlikely to have the same function as renalase1 and 2. Indeed,
hRenalase3 lacks a significant portion of the amine oxidase
domain, as does hRenalase4, which, in addition, has neither a
signal peptide nor an FAD-binding site. The functional
significance of the spliced isoforms is not known. As only
hRenalase1 is detected in plasma, perhaps the others have a
paracrine function, or play a role in intracellular substrate
metabolism. Unlike hRenalase2, hRenalase1 is efficiently
secreted by transfected mammalian cells. hRenalase3 and 4
have not been tested, but they are unlikely to be secreted, and
may have different enzymatic function, or none at all.
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Figure 1 |Renalase isoforms. The 10 exons of the renalase gene
are numbered. Of the nine possible isoforms, only those (renalase
1, 2, 3, 4) for which mRNA data are available are shown.
aa: amino acids.
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Figure 2 | Functional domains of renalase. Signal peptide
(aa 1–17); FAD (flavin adenine dinucleotide) binding
site (aa B3–42); amino oxidase domain (aa B75–335).
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hRenalase1 can be detected in plasma using a polyclonal
antibody raised against a glutathione S transferase-renalase
fusion protein.14 Plasma levels are markedly reduced in
patients with ESRD, suggesting that the kidney is the
predominant organ that secretes renalase and regulates
circulating levels. It is currently not understood why
other tissues, such as the heart, skeletal muscle. and liver,
that express renalase do not compensate by increasing
production and secretion. It is noteworthy that subtotal
nephrectomy is associated with left ventricular hypertrophy,
and a significant decrease in heart hRenalase1 levels in
neonatal and adult rats.15,16
The mouse gene has been cloned and characterized.17
Mouse renalase consists of seven exons and resides in mouse
chromosome 19C1. The mouse renalase protein (mRenalase)
has 72% amino acid identity with hRenalase, and contains a
putative signal peptide, an FAD-binding site, and an amine
oxidase domain. mRenalase can be expressed in prokaryotic
and eukaryotic cells, and is observed to be secreted out of
human cell lines. Interestingly, the mRenalase gene is highly
expressed not only in the kidney, but also in the testicle,
suggesting that the testicle may be a significant source of
secreted renalase.
Recombinant hRenalase1 was screened for amine oxidase
activity, as it contained an FAD-binding site and an amine
oxidase domain. Of the amines tested, only catecholamines
were metabolized by recombinant renalase1. On the basis of
its amino-acid sequence, and substrate specificity, it is
concluded that renalase belongs to a new class of FAD-
containing amine oxidases. When injected into rodents,
recombinant hRenalase1 leads to a transient, dose-dependent
fall in blood pressure, heart rate, myocardial contractility, and
peripheral vascular resistance.14
RENALASE ACTIVATION
Under basal conditions, the human plasma lacks significant
amine oxidase activity.18 We had confirmed that renalase
activity could not be detected under basal conditions,
suggesting that unlike refolded recombinant renalase, native
renalase either has no amine oxidase activity or may circulate
as a proenzyme that requires specific signals for activation.
We tested if a sudden increase in plasma catecholamines,
achieved by infusing exogenous epinephrine, represents such
a signal, and found that renalase activity increased by
approximately 10-fold within 30 s, for at least 60min.14,15
The rapid increase in activity most likely represents the
activation of circulating renalase, and not de novo secretion.
Within 15min after epinephrine administration, plasma
renalase increases by two- to three-fold, indicating a delayed
renalase secretion. Of note, as blood pressure also increases
with epinephrine administration, it is difficult to precisely
determine if activation and secretion are mediated by an
increase in plasma catecholamines, a rise in blood pressure,
or by both. The kinetics of activation were examined using
doses of epinephrine chosen to increase systolic blood
pressure by 2–110mm/Hg. Plasma renalase is fully activated
when systolic blood pressure increases by 7mm/Hg over
baseline, suggesting that renalase plays a role in the minute-
to-minute regulation of blood pressure. It is noteworthy that
even a 10-fold increase in renalase activity may not
significantly alter plasma catecholamine levels.18 As discussed
in more detail below, renalase administration provides
significant protection against cardiac ischemia, and it is
therefore likely that renalase has additional, and perhaps
more relevant, enzymatic functions.
The molecular mechanisms that mediate the acute
activation of renalase in vivo are not yet understood. One
possibility is that increased catecholamines could cause a
conformational change in the renalase molecule, with the
subsequent dissociation of an inhibitor or binding of a
circulating activator. Alternatively, activation may involve the
proteolytic cleavage of blood renalase. Given that the FAD-
binding site is at the extreme amino terminus (amino acid
3–42), and the amine oxidase domain extends from amino 75
to 335, it is unlikely that a significant portion of the molecule
could be cleaved without affecting enzymatic activity.
Perhaps a small segment can be removed at either the amino
or carboxyl terminus. Finally, active renalase may be a dimer,
and enzymatic activity could be modulated through the
formation of dimers. This is an attractive hypothesis as the
active form of many amine oxidases, including monoamine
oxidase-A and monoamine oxidase-B, is a dimer.
RENALASE DEFICIENCY AND HYPERTENSION
As a number of factors are known to contribute to the
development of hypertension in patients with CKD and
ESRD, it is important to determine the contribution of
renalase to that process. Data obtained from different
experimental approaches indicate that renalase deficiency,
in the absence of significant kidney disease, is associated with
hypertension. Renalase gene expression can be downregu-
lated in the rat using small inhibitory RNAs, without
affecting renal function.19 The mean arterial pressure
increased by 12mm/Hg, and the hypertensive response to
exogenous catecholamines was markedly increased in the
inhibitory RNA-treated animals. Dahl salt-sensitive rats
develop moderately severe hypertension, increased sympa-
thetic activity, and elevated catecholamines when maintained
on a high-salt diet. Systolic blood pressure increased by
20mm/Hg after 3 weeks on an 8% salt diet, and renalase
expression decreased by 70%.
To further evaluate the role of renalase in the regulation of
blood pressure, we generated a renalase knockout (KO)
mouse by disrupting the renalase locus using homologous
recombination.20 The targeting construct deletes the promo-
ter region and a large part of the coding region. Gene
disruption was confirmed by PCR and western blot. Renalase
KO mice weighted 25% less than control animals. Renal
function, kidney histology, and plasma aldosterone levels are
indistinguishable from those of wild-type littermates. He-
modynamic monitoring by telemetry indicates an increased
heart rate and blood pressure in the renalase KO, with a
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relatively greater elevation in diastolic pressure. Mean arterial
pressure is significantly elevated in KO both during activity
and at rest. Taken together, these data suggest that renalase
deficiency is associated with tachycardia and hypertension.
The relatively greater increase in diastolic pressure suggests
significant vasoconstriction in the renalase KO, as would be
expected if renalase played a significant role in catecholamine
metabolism. Renalase seems to play a key role in the
regulation of ambulatory blood pressure in mice.
Finally, Zhao et al.21 tested for association of the renalase
gene with essential hypertension by examining eight single-
nucleotide polymorphisms of the renalase gene in 2586
individuals (1317 hypertensive cases and 1269 normotensive
controls) from the International Collaborative Study of
Cardiovascular Disease in Asia (InterASIA in China). Two
single-nucleotide polymorphisms (rs2576178 GG genotype
and rs2296545 CC) were associated with essential hyperten-
sion. Interestingly, rs2296545 CC results in an amino acid
change (glutamic to aspartic acid at amino acid 37) within
the FAD-binding domain, and it is tempting to speculate that
this conservative amino acid change may weaken FAD
binding and affect the function of renalase. These findings
provide novel genetic susceptibility markers for essential
hypertension, as well as novel insights for the mechanism of
development of essential hypertension.
RENALASE DEFICIENCY IN CKD
Rats subjected to the removal of approximately 85% of
kidney tissue (5/6 Nx) develop chronic renal failure and
most of the associated abnormalities, including increased
sympathetic activation, hypertension, and left ventricular
hypertrophy. The 5/6 Nx rat is considered to be an excellent
animal model of CKD. These animals develop severe
blood renalase deficiency 2–3 weeks post-surgery.15 Renalase
levels in kidney and heart tissues were examined by
immunocytochemistry and found to be markedly reduced.
Renalase activation by catecholamines was also shown to be
abnormal in 5/6 Nx rats. Although an epinephrine infusion
can activate blood renalase in 5/6 Nx rats, the magnitude
and duration of the activation were significantly lower than
those which were observed in control rats. Taken together,
these data demonstrate that there is a marked decrease of
renalase protein and renalase activity in 5/6 Nx rats, and
renalase deficiency may contribute to elevated plasma
catecholamine levels.
As cardiac NE, a renalase substrate, increases by 600-fold
during cardiac ischemia, and given that renalase is expressed
in the heart, we tested whether recombinant renalase had a
protective effect on the myocardium during ischemia. In the
isolated perfused mouse heart models, left ventricular
function was better preserved in hearts perfused with
renalase, with left ventricular pressure being 85 and 47% of
baseline at 120min for renalase and glutathione S transferase,
a control protein, respectively.22 Renalase also decreased the
myocardial infarct size by 54%. The data indicate that
renalase reduces myocardial damage during acute ischemia,
and its expression in the heart is decreased in CKD. We
speculate that cardiac renalase deficiency may partly explain
the increased susceptibility to ischemic myocardial damage
and ventricular arrhythmias observed in patients with CKD.
THE RENALASE PATHWAY
In summary, renalase is a novel FAD-dependent amine
oxidase that is secreted into blood by the kidney. Recombi-
nant renalase lowers blood pressure in vivo by decreasing
cardiac output and peripheral vascular tone. Renalase seems
to be secreted as a proenzyme, which can be activated by
catecholamines. It is likely that renalase not only degrades
catecholamines, but also metabolizes additional substrates.
And it is possible that these yet unidentified substrates will
turn out to be more relevant to renalase’s physiological role
and cardioprotective properties. Plasma renalase is signifi-
cantly reduced in patients with CKD/ESRD, and the
activation pathway is defective in rats with CKD. Interest-
ingly, CKD is associated with a marked reduction in cardiac
renalase expression, and the renalase KO is more susceptible
to cardiac ischemic damage. These data support the notion
that renalase plays an important role in the regulation of
blood pressure and in the prevention of cardiac ischemic
damage, and that its deficiency may account for the increased
cardiovascular risk in patients with CKD (Figure 3). We
speculate that renalase replacement therapy will improve
cardiovascular outcome in CKD.
DISCLOSURE
Patent application submitted for the use of renalase.
ACKNOWLEDGMENTS
This study was supported by Veterans Administration (Merit Review
award) and Grant DK48105B from the National Institutes of Health.
REFERENCES
1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all
patients on dialysis, patients on dialysis awaiting transplantation, and
recipients of a first cadaveric transplant. N Engl J Med 1999; 341:
1725–1730.
2. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant
stress and inflammation in patients with moderate to severe chronic
kidney disease. Kidney Int 2004; 65: 1009–1016.
CKD and ESRD
Cardiac
renalase
Plasma
renalase
Kidney
renalase
Cardiac
ischemia
Hypertension Renal
ischemia
Figure 3 |Pathophysiology of renalase. CKD: chronic kidney
disease; ESRD: end-stage renal disease; dotted lines: speculative
link.
Kidney International (2009) 76, 366–370 369
GV Desir: Cardiac function and blood pressure by renalase m in i rev iew
3. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity
in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15:
524–537.
4. Joles JA, Koomans HA. Causes and consequences of increased
sympathetic activity in renal disease. Hypertension 2004; 43:
699–706.
5. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal
dysfunction and cardiovascular outcomes after myocardial infarction.
N Engl J Med 2004; 351: 1285–1295.
6. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of
death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:
1296–1305.
7. DiBona GF. Neural control of renal function: role of renal alpha
adrenoceptors. J Cardiovasc Pharmacol 1985; 7(Suppl 8): S18–S23.
8. DiBona GF. Neural control of renal function: cardiovascular implications.
Hypertension 1989; 13: 539–548.
9. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in
end-stage renal disease. Circulation 2002; 106: 1974–1979.
10. Converse Jr RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity
in patients with chronic renal failure. N Engl J Med 1992; 327:
1912–1918.
11. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity is
inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003;
14: 3239–3244.
12. Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric
hypertrophy in patients with end-stage renal disease. Hypertension 2002;
40: 41–46.
13. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts
survival and incident cardiovascular events in patients with end-stage
renal disease. Circulation 2002; 105: 1354–1359.
14. Xu J, Li G, Wang P et al. Renalase is a novel, soluble monoamine oxidase
that regulates cardiac function and blood pressure. J Clin Invest 2005;
115: 1275–1280.
15. Li G, Xu J, Wang P et al. Catecholamines regulate the activity, secretion,
and synthesis of renalase. Circulation 2008; 117: 1277–1282.
16. Ghosh SS, Krieg KJ, Sica DA et al. Cardiac hypertrophy in neonatal
nephrectomized rats: the role of the sympathetic nervous system. Pediatr
Nephrol 2009; 24: 367–377.
17. Wang J, Qi S, Cheng W et al. Identification, expression and tissue
distribution of a renalase homologue from mouse. Mol Biol Rep 2008; 35:
613–620.
18. Boomsma F, Tipton KF. Renalase, a catecholamine-metabolising enzyme?
J Neural Transm 2007; 114: 775–776.
19. Ghosh SS, Gehr TWB, Sica DA et al. Effect of renalase inhibition on blood
pressure. J Am Soc Nephrology 2006; 17: 208A.
20. Desir GV, Wu Y, Wang P et al. Renalase deficiency increases sympathetic
tone and causes hypertension. J Am Soc Nephrol 2008. Available at http://
www.asn-online.org/education_and_meetings/renal_week/archives/
21. Zhao Q, Fan Z, He J et al. Renalase gene is a novel susceptibility gene for
essential hypertension: a two-stage association study in northern Han
Chinese population. J Mol Med 2007; 85: 877–885.
22. Desir GV, Li Y, Liu D et al. Downregulation of cardiac renalase expression
in CKD, and protective effect of renalase in acute coronary syndrome.
J Am Soc Nephrol 2007; 18: 149A.
370 Kidney International (2009) 76, 366–370
min i rev iew GV Desir : Cardiac function and blood pressure by renalase
